{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:30Z","timestamp":1786982190235,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate disease activity status using the Acromegaly Disease Activity Tool (ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) in a cohort of Spanish acromegaly patients, to assess the relationship between the level of disease activity according to both ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and the physicians\u2019 clinical evaluation, and to study the potential discrepancies in the perception of symptoms between physicians and patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicenter, observational, descriptive and cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Disease activity was assessed in adult patients with acromegaly under pharmacological treatment during at least 6 months using ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , 48.2%, 31.8% and 20.0% of a total of 111 patients were classified as having a stable disease (S), mild disease activity (M-DA) and significant disease activity (S-DA) respectively. ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      classification of disease activity significantly correlated with physicians\u2019 opinion, with a moderate inter-rater agreement and a specificity of 92.45% (PPV\u2009=\u200986.21%). No correlation was found between IGF-I levels and severity of symptoms or quality of life (QoL). A decision to take clinical action was significantly more frequent in S-DA and M-DA patients than S patients but no action was taken on 5 (22.7%) and 27 (77.1%) S-DA and M-DA patients, respectively\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      detected disease activity in 51.8% of patients. Interestingly, although M-DA and S-DA patients were likely to be in the process of being controlled, action was not always taken on these patients. ACRODAT\n                      <jats:sup>\u00ae<\/jats:sup>\n                      is a validated and highly specific tool that may be useful to routinely monitor acromegaly and to identify patients with non-obvious disease activity by incorporating \u201cpatient-centred\u201d parameters like symptoms and QoL to the clinical evaluation of acromegaly.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-021-02900-0","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T17:20:34Z","timestamp":1634664034000},"page":"525-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Acromegaly disease activity according to ACRODAT\u00ae, a cross-sectional study in Spain: ACROVAL study"],"prefix":"10.1007","volume":"75","author":[{"given":"M\u00f3nica","family":"Marazuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bernabeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelmiro","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Paja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampedro-Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Luz","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"D\u00edaz-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez-Cenizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"issue":"9","key":"2900_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass et al. A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u201361. (2018)","journal-title":"Nat. Rev. Endocrinol"},{"issue":"1","key":"2900_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11102-016-0772-8","volume":"20","author":"L Vilar","year":"2017","unstructured":"L. Vilar, C.F. Vilar, R. Lyra, R. Lyra, L.A. Naves, Acromegaly: clinical features at diagnosis. Pituitary. 20(1), 22\u201332 (2017)","journal-title":"Pituitary."},{"issue":"1","key":"2900_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102\u2013152 (2004)","journal-title":"Endocr. Rev."},{"issue":"2","key":"2900_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159(2), 89\u201395 (2008)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"2900_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2265.1994.tb03789.x","volume":"41","author":"C Rajasoorya","year":"1994","unstructured":"C. Rajasoorya, I.M. Holdaway, P. Wrightson, D.J. Scott, H.K. Ibbertson, Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf) 41(1), 95\u2013102 (1994)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"2900_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11102-018-00933-9","volume":"22","author":"Y Jackson","year":"2019","unstructured":"Y. Jackson, E. Flood, S. Rhoten, E.M. Janssen, M. Lundie, AcroVoice: eliciting the patients\u2019 perspective on acromegaly disease activity. Pituitary. 22(1), 62\u201369 (2019)","journal-title":"Pituitary."},{"issue":"6","key":"2900_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11102-013-0544-7","volume":"17","author":"H Kepicoglu","year":"2014","unstructured":"H. Kepicoglu, E. Hatipoglu, I. Bulut, E. Darici, N. Hizli, P. Kadioglu, Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary. 17(6), 557\u2013563 (2014)","journal-title":"Pituitary."},{"issue":"11","key":"2900_CR8","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1210\/jc.2011-1645","volume":"96","author":"J Tiemensma","year":"2011","unstructured":"J. Tiemensma, A.A. Kaptein, A.M. Pereira, J.W. Smit, J.A. Romijn, N.R. Biermasz, Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J. Clin. Endocrinol. Metab. 96(11), 3550\u20133558 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2900_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2265.2005.02307.x","volume":"63","author":"R Trepp","year":"2005","unstructured":"R. Trepp, R. Everts, C. Stettler, S. Fischli, S. Allemann, S.M. Webb et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin. Endocrinol. (Oxf) 63(1), 103\u2013110 (2005)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"11","key":"2900_CR10","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933\u20133951 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"2900_CR11","doi-asserted-by":"publisher","first-page":"457 e1","DOI":"10.1016\/j.endonu.2013.01.012","volume":"60","author":"F Cordido","year":"2013","unstructured":"F. Cordido, J.A. Garcia Arnes, M. Marazuela Aspiroz, E. Torres Vela; grupo de Neuroendocrinologia de la Sociedad Espanola de Endocrinologia y N., [Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinologia de la Sociedad Espa\u00f1ola de Endocrinologia y Nutricion]. Endocrinol. Nutr. 60(8), 457 e1\u2013e15 (2013)","journal-title":"Endocrinol. Nutr."},{"issue":"10","key":"2900_CR12","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJ Neggers","year":"2008","unstructured":"S.J. Neggers, M.O. van Aken, W.W. de Herder, R.A. Feelders, J.A. Janssen, X. Badia et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93(10), 3853\u20133859 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"2900_CR13","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1007\/s11102-013-0519-8","volume":"17","author":"M Guitelman","year":"2014","unstructured":"M. Guitelman, A. Abreu, A.L. E-d-l-M, M. Mercado, Patient-focussed outcomes in acromegaly. Pituitary. 17(Suppl 1), S18\u2013S23 (2014)","journal-title":"Pituitary."},{"issue":"2","key":"2900_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.1.02214","volume":"155","author":"SM Webb","year":"2006","unstructured":"S.M. Webb, X. Badia, N.L. Surinach; Spanish AcroQol Study G., Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur. J. Endocrinol. 155(2), 269\u201377 (2006)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"2900_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2265.2009.03773.x","volume":"73","author":"C Sievers","year":"2010","unstructured":"C. Sievers, K. Brubach, B. Saller, H.J. Schneider, M. Buchfelder, M. Droste et al. Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin. Endocrinol. (Oxf) 73(1), 89\u201394 (2010)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"9","key":"2900_CR16","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/art.34543","volume":"64","author":"P Studenic","year":"2012","unstructured":"P. Studenic, H. Radner, J.S. Smolen, D. Aletaha, Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum. 64(9), 2814\u20132823 (2012)","journal-title":"Arthritis Rheum."},{"issue":"5","key":"2900_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jpainsymman.2015.12.309","volume":"51","author":"K Webber","year":"2016","unstructured":"K. Webber, A.N. Davies, M.R. Cowie, Disparities between clinician and patient perception of breakthrough pain control. J. Pain Symptom Manage. 51(5), 933\u2013937 (2016)","journal-title":"J. Pain Symptom Manage."},{"issue":"6","key":"2900_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-017-0835-5","volume":"20","author":"AJ van der Lely","year":"2017","unstructured":"A.J. van der Lely, R. Gomez, A. Pleil, X. Badia, T. Brue, M. Buchfelder et al. Development of ACRODAT((R)), a new software medical device to assess disease activity in patients with acromegaly. Pituitary. 20(6), 692\u2013701 (2017)","journal-title":"Pituitary."},{"key":"2900_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1477-7525-2-13","volume":"2","author":"X Badia","year":"2004","unstructured":"X. Badia, S.M. Webb, L. Prieto, N. Lara, Acromegaly quality of life questionnaire (AcroQoL). Health Qual. Life Outcomes 2, 13 (2004)","journal-title":"Health Qual. Life Outcomes"},{"issue":"16","key":"2900_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171\u20131177 (2000)","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"2900_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000375451","volume":"103","author":"SM Webb","year":"2016","unstructured":"S.M. Webb, X. Badia, Quality of life in acromegaly. Neuroendocrinology. 103(1), 106\u2013111 (2016)","journal-title":"Neuroendocrinology."},{"issue":"1","key":"2900_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1365-2265.2007.02836.x","volume":"67","author":"A Pokrajac","year":"2007","unstructured":"A. Pokrajac, G. Wark, A.R. Ellis, J. Wear, G.E. Wieringa, P.J. Trainer, Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin. Endocrinol. (Oxf) 67(1), 65\u201370 (2007)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"8","key":"2900_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1373\/clinchem.2013.205070","volume":"59","author":"A Algeciras-Schimnich","year":"2013","unstructured":"A. Algeciras-Schimnich, D.E. Bruns, J.C. Boyd, S.C. Bryant, K.A. La Fortune, S.K. Grebe, Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions. Clin. Chem. 59(8), 1187\u20131194 (2013)","journal-title":"Clin. Chem."},{"issue":"3","key":"2900_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4158\/EP14330.OR","volume":"21","author":"PU Freda","year":"2015","unstructured":"P.U. Freda, M.B. Gordon, N. Kelepouris, P. Jonsson, M. Koltowska-Haggstrom, A.J. van der Lely, Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr. Pract. 21(3), 264\u2013274 (2015)","journal-title":"Endocr. Pract."},{"issue":"4","key":"2900_CR25","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"A.Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), e937\u2013e946 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2900_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667\u201378. (2020)","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"2","key":"2900_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11102-015-0691-0","volume":"19","author":"I Bernabeu","year":"2016","unstructured":"I. Bernabeu, A. Pico, E. Venegas, J. Aller, C. Alvarez-Escola, J.A. Garcia-Arnes et al. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 19(2), 127\u2013137 (2016)","journal-title":"Pituitary."},{"issue":"2","key":"2900_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","volume":"22","author":"R Camara","year":"2019","unstructured":"R. Camara, E. Venegas, J.A. Garcia-Arnes, F. Cordido, J. Aller, M.L. Samaniego et al. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study. Pituitary. 22(2), 137\u201345. (2019)","journal-title":"Pituitary."},{"issue":"3","key":"2900_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11102-018-0884-4","volume":"21","author":"MJ van Esdonk","year":"2018","unstructured":"M.J. van Esdonk, E.J.M. van Zutphen, F. Roelfsema, A.M. Pereira, P.H. van der Graaf, N.R. Biermasz et al. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary. 21(3), 310\u201322. (2018)","journal-title":"Pituitary."},{"issue":"4","key":"2900_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/EJE-14-0844","volume":"172","author":"C Schofl","year":"2015","unstructured":"C. Schofl, M. Grussendorf, J. Honegger, A. Tonjes, D. Thyroke-Gronostay, B. Mayr et al. Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur. J. Endocrinol. 172(4), 351\u2013356 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"2900_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/EJE-19-0794","volume":"182","author":"NA Tritos","year":"2020","unstructured":"N.A. Tritos, A.F. Mattsson, G. Vila, B.M.K. Biller, A. Klibanski, S. Valluri et al. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur. J. Endocrinol. 182(3), 285\u201392. (2020)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"2900_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/EJE-12-0602","volume":"168","author":"C Schofl","year":"2013","unstructured":"C. Schofl, H. Franz, M. Grussendorf, J. Honegger, C. Jaursch-Hancke, B. Mayr et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur. J. Endocrinol. 168(1), 39\u201347 (2013)","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"2900_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40618-017-0773-0","volume":"41","author":"M Ragonese","year":"2018","unstructured":"M. Ragonese, S. Grottoli, P. Maffei, A. Alibrandi, M.R. Ambrosio, G. Arnaldi et al. How to improve effectiveness of pegvisomant treatment in acromegalic patients. J. Endocrinol. Invest. 41(5), 575\u201381. (2018)","journal-title":"J. Endocrinol. Invest."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02900-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T06:20:16Z","timestamp":1699683616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02900-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2900"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02900-0","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L.S.-C. and M.D.-M. are employees of Pfizer (Spain). M.L.S. works for Pfizer (Spain). M.M., C.B., I.B., E.M., R.V., M.P., M.S.-N. have received compensation from Pfizer (Spain) for their participation as investigators of ACROVAL study. M.M. has received compensation from Pfizer (Spain) for their participation as research coordinator of ACROVAL study. M.M., I.B. and M.P. have received speaker honoraria from Pfizer (Spain). M.M., I.B. and M.S.-N. have received speaker honoraria from Novartis. M.M. and C.B. have received speaker honoraria from Ipsen. M.M. has participated in advisory boards for Ipsen, Novartis and Pfizer (Spain). I.B. is a grant recipient and advisory board member for Pfizer. This study was sponsored by Pfizer. Medical writing support was provided by Esther Tapia PhD, and was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}